Yale Image Finder

Search the actual image content of 1,538,051 (and growing!) Open Access images and figures from PubMed Central.


Advanced...

Related Figures


Figure 4 (a): Overall survival of patients with h...

Figure 2 Comparison of overall survival between p...

Figure 3 Comparison of progression-free survival ...

Figure 1 Progression-free survival and overall su...

Figure 3 The progression-free survival curves for...

Figure 1 Overall survival after radiotherapy for ...

Fig. 1 Kaplan-Meier survival analysis; overall ...

Figure 2 Overall survival of patients with high-r...

Figure 2 Overall survival according to adjuvant r...

Figure 1 The number of surviving crypts per circu...

Figure 1: Median progression-free survival and overall survival in patients with newly diagnosed anaplastic oligodendroglioma treated with radiotherapy alone or radiotherapy plus PCV (procarbazine, CCNU, and vincristine) (van den Bent et al 2006).

Image Text (High Precision): Progression free months overall radiotherapy survival

Other Images from "Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors":


Figure 1 Median progression-free survival and ove...

Figure 2 Percentage of patients with progression-...

[Full Text] [PDF]

Abstract

Procarbazine HCl is a ‘nonclassical’ oral alkylating anticancer agent that was first synthesized in the late 1950s. It has been used in the treatment of many cancers, but its main use is in the treatment of Hodgkin’s lymphoma and brain tumors and, to a lesser extent, Non-Hodgkin’s lymphoma and primary central nervous system lymphoma. Procarbazine is a prodrug that undergoes metabolic transformation into active intermediates that are thought to inhibit DNA, RNA, and protein synthesis. Early use of procarbazine in combination with mechlorethamine, vincristine, and prednisone (MOPP) was effective in the treatment of advanced Hodgkin’s lymphoma, but late toxic effects such as secondary cancer and infertility led to its replacement by other regimens. However, its recent reintroduction in the dose-intensified BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen has yielded very promising findings. Procarbazine alone, or more commonly combined in the PCV (procarbazine, lomustine [CCNU], and vincristine) regimen, is also effective in treating gliomas comprising astrocytomas, glioblastomas, and oligodendrogliomas. The most common side effects of procarbazine are gastrointestinal disturbances, myelosuppression, and central nervous system effects. In conclusion, the use of procarbazine in combination with other drugs means that it remains a major anticancer drug in the management of Hodgkin’s lymphoma and gliomas.


Search: Image Text (High Recall) Image Text (High Precision) Caption Abstract Title Full Text

All images and content copyright their respective owners. All else copyright ©2007-2008, Krauthammer Lab, Yale University.

Sign up for Yale Image Finder announcements:

Email: